Glenmark becomes first company to launch triple fixed-dose combination for type 2 diabetes in India

Glenmark Pharmaceuticals Limited on Wednesday announced that it has launched the first triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India.

According to the company, Teneligliptin is a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor).

“This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation,” the company stated on Wednesday.

Also Read

As Dr. Reddy’s Q4 profit soars to Rs. 959 crore, licensing deals, innovative products and consumer health to be priority in FY24

French drugmaker Sanofi to demerge its consumer business in India

Glenmark Pharmaceuticals launches India’s first Topical Minocycline 4% Gel for moderate to severe acne

70-80% of APIs are imported from China; We are working towards filling this gap: Dr. Sanjay Chaturvedi, CEO, IOL Chemicals and Pharmaceuticals

This offers patients with Type 2 diabetes the convenience of once-daily dosing to improve their glycemic control and achieve the targeted HbA1c within 24 weeks, the company stated.

“Type 2 diabetes patients in India often face issues of beta cell dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is 38% compared to the global incidence of 15%. Being a leader in diabetes therapy in the country, we are proud to introduce Zita-PioMet, India’s first triple fixed-dose combination for high insulin-resistant type 2 diabetes. The innovative, effective, and affordable drug will help improve glycemic control among adult patients with high HbA1c,” Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals Ltd., said on Wednesday.

Glenmark has been a key player in the diabetes market and it has introduced new, effective and affordable treatment options for diabetic patients, especially the ones with uncontrolled Type 2 diabetes.

Earlier this year, Glenmark also launched Sitagliptin (Sitazit) and its FDCs, followed by Lobeglitazone (LOBG) and FDCs of Teneligliptin including its combinations with Pioglitazone (Zita Pio) and Dapagliflozin (Zita-D).

In 2019, Glenmark later launched Remogliflozin (Remo and Remozen), a novel SGLT‐2 inhibitor, and subsequently, its combinations with Metformin and Vildagliptin (Remo-V, Remozen-V, Remo MV, and Remozen MV).

In 2015, Glenmark was the first to launch the DPP4 inhibitor, Teneligliptin (Zita Plus and Ziten), followed by an FDC of Teneligliptin + Metformin (Zita-Met Plus and Ziten-M).